Pharmacogenetic Dosing Algorithm

Uses

How it works

Benefits

Evidence quality

Highlighted claims

• The study plans to develop a pharmacogenetic algorithm for initial TB drug dosing that predicts initiation doses to rapidly achieve therapeutic exposure while reducing time to target concentration. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• Algorithm development will initially focus on isoniazid and bedaquiline because pharmacogenetic markers are known or suspected to influence their clearance. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• The expected outputs of the dosing algorithm include ancestry-informed dosing recommendations and a preliminary predictive tool for future clinical validation in Southern African cohorts. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• External validation of the dosing algorithm will use data from other PoPG sites across Southern Africa. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
• Machine-learning integration in the algorithm will use Bayesian mixed-effects models and stratified linkage disequilibrium score regression to estimate the proportion of dose-response variability explained by genetics, ancestry and clinical covariates. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort